American Oriental Bioengineering (广西博科药业) continued to perform well financially in 2008, even though its corporate business developments sometimes confuse and frustrate investors. The company said 2008 revenues were up 65% to $264.6 million. Non-GAAP net income rose 45% to $62.7 million. Both numbers show admirable upside progress. American Oriental’s stock price does not fully reflect its last three years of strong financial performance, though some of the problem may be the fault of American Oriental. More details...

Stock Symbol: (NYSE: AOB)